Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy Clinical Trial

Official title:

Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01364597
• Other study ID #: N01266
• Secondary ID: 2011-000374-60
• Status: Completed
• Phase: Phase 3
• Start date: August 1, 2011
• Est. completion date: February 3, 2022

Study information

• Verified date: November 2023
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.

Description:

This is a Phase 3, open-label, single-arm, multicenter, long-term study to evaluate the safety and efficacy of brivaracetam (BRV) in children with epilepsy.

This study was initially designed for pediatric subjects who had completed a previous BRV study.

With protocol amendment 4, enrollment for "directly enrolled" subjects was modified from 'up to' an additional 100 subjects to "at least" 100 subjects, keeping the planned total enrollment of approximately 600 subjects to allow flexibility in the number of patients reaching 1 year of exposure.

With protocol amendment 5, entry criteria for subjects coming for other pediatric core studies in development were included. Additional clarity was provided for subjects enrolled in N01266 that temporary roll over to one of those studies and resume participation in N01266.

With protocol amendment 6, central EEG reading and entry visit EEG were removed. Some clarifications on study assessments (questionnaires, EEGs) was provided and inclusion criteria were aligned from an earlier local amendment.

With protocol amendment 7, the pregnancy section was updated to clarify that Pregnancy Report and Outcome Form has to be completed in all pregnancies.

With protocol amendment 8, re-categorization of study variables in compliance with reporting registries was performed. Modifications due to COVID19 pandemic were implemented and clarification provided that participants may transition to another BRV study.

The primary objective is to evaluate the long-term safety and tolerability of BRV. The secondary objective is to assess the efficacy of BRV during long-term exposure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 257
• Est. completion date: February 3, 2022
• Est. primary completion date: February 3, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 28 Days to 17 Years

Eligibility

Inclusion Criteria:

All Subjects:

• Informed Consent form (ICF) is signed and dated by the parent(s) or legal representative(s)

• Subject/legal representative is considered reliable and capable of adhering to the protocol

• For female subjects:

• Subject is not of childbearing potential

OR if women of childbearing potential, and sexually active only if:

• Adequate Contraceptive method

• Negative pregnancy test

• Understands the consequences and potential risks of inadequately protected sexual activity, understands and properly uses contraceptive methods, and is willing to inform the Investigator of any contraception changes

Long Term Follow-up Subjects:

• Male or female subjects having participated in a core study with a confirmed diagnosis of epilepsy and for whom a reasonable benefit from long-term administration of BRV is expected

Directly Enrolled Subjects:

• Subject is a male or female =4 years to <17 years of age

• Subject has a clinical diagnosis of partial-onset seizures (POS) according to the International League Against Epilepsy (ILAE) classification

• Subject has an EEG compatible with the clinical diagnosis of POS

• Subject has been observed to have uncontrolled POS after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED; concurrently or sequentially)

• Subject had at least 1 seizure (POS) during the 3 weeks before the Screening Visit (ScrV)

• Subject is taking at least 1 AED. All AEDs need to be at a stable dose for at least 7 days before the ScrV. Vagal nerve stimulator stable for at least 2 weeks before the ScrV is allowed and will be counted as a concomitant AED. Benzodiazepines taken more than once a week (for any indication) will be considered as a concomitant AED

Exclusion Criteria:

All Subjects:

• Subject is a pregnant or nursing female

• Subject has severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the subject.

• Subject has planned participation in any clinical study of another investigational drug or device.

• Subject has >1.5x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (=1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%). N01349 subjects with a total bilirubin > ULN may be considered for the study if benign unconjugated hyperbilirubinemia is suspected in the context of prolonged neonatal jaundice, after discussion with the medical monitor. For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the eCRF. If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at the baseline referenced in Table 5-1 for LTFU subjects and at the Screening Visit for directly enrolled subjects, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor. Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation. This includes re-screening.

• Subject has chronic liver disease.

Long Term Follow-up Subjects:

• Subject had hypersensitivity to BRV or excipients or comparative drugs as stated in this protocol during the course of the core study.

• Subject had poor compliance with the visit schedule or medication intake in the core study.

• Subject =6 years of age has a lifetime history of suicide attempt (including actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the EV. If a subject has active suicidal ideation without a specific plan as indicated by a positive response ("Yes") to Question 4 of Columbia-Suicide Severity Rating Scale (C SSRS) at the EV, the subject should be referred immediately to a Mental Healthcare Professional and may be excluded from the study based upon the Investigator's judgment of benefit/risk of continuing the subject in the study/on study medication.

Directly Enrolled Subjects:

• Subject has previously received BRV.

• Subject had concomitant use of LEV at the ScrV. In addition, the use of LEV is prohibited for at least 4 weeks prior to the ScrV.

• Subject has epilepsy secondary to a progressive cerebral disease or tumor, or any other progressively neurodegenerative disease. Stable arteriovenous malformations, meningiomas or other benign tumors may be acceptable according to Investigator's opinion.

• Subject has a history of primary generalized epilepsy.

• Subject has a history of status epilepticus in the month immediately prior to the ScrV or during the Up Titration Period.

• Subject has a history or presence of pseudoseizures.

• Subject is suffering only from febrile seizures.

• Subject is on felbamate with less than 18 months continuous exposure. Subject who has taken felbamate for a combined duration of treatment and wash out of <18 months before the ScrV.

• Subjects treated with vigabatrin who have visual field defects.

• Subject has an allergy to pyrrolidone derivatives or investigational product excipients or a history of multiple drug allergies.

• Subject has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow depression, chronic hepatic disease, severe renal impairment, psychiatric disorder).

• Subject has an underlying disease or is receiving a treatment that may interfere with the absorption, distribution, metabolism, and elimination of the study drug.

• Subject has any medical condition that might interfere with his/her study participation (eg, serious infection or scheduled elective surgery).

• Subject has a terminal illness.

• Subject has any clinically significant deviations from reference range values for laboratory parameters as determined by the Investigator.

• Subject has a clinically relevant ECG abnormality according to the Investigator.

• Subject had major surgery within 6 months prior to the ScrV.

• Subject received any investigational drug or device within the 30 days prior to the ScrV.

Related Conditions & MeSH terms

• Epilepsy

Intervention

Drug:
• Brivaracetam (BRV)
The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight >40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights >50kg) is reached.

Locations

Country	Name	City	State
Belgium	N01266 202	Brussels
Belgium	N01266 203	Brussels
Belgium	N01266 201	Leuven
Belgium	N01266 204	Leuven
Czechia	N01266 502	Hradec Králové
Czechia	N01266 504	Ostrava Prouba
Czechia	N01266 240	Praha 4
France	N01266 207	Lille cedex
France	N01266 206	Paris
Germany	N01266 218	Bayern
Germany	N01266 209	Freiburg
Hungary	N01266 210	Budapest
Hungary	N01266 224	Budapest
Hungary	N01266 247	Budapest
Hungary	N01266 222	Debrecen
Hungary	N01266 232	Miskolc
Ireland	N01266 211	Cork
Italy	N01266 212	Messina
Italy	N01266 213	Parma
Italy	N01266 238	Pavia
Italy	N01266 239	Pavia
Italy	N01266 230	Roma
Italy	N01266 256	Roma
Mexico	N01266 223	Aguascalientes
Mexico	N01266 611	Chihuahua
Mexico	N01266 609	Culiacán
Mexico	N01266 603	Guadalajara
Mexico	N01266 610	Monterrey
Poland	N01266 404	Bialystok
Poland	N01266 403	Gdansk
Poland	N01266 406	Kielce
Poland	N01266 402	Kraków
Poland	N01266 401	Poznan
Poland	N01266 407	Szczecin
Poland	N01266 405	Wroclaw
Spain	N01266 309	Barcelona
Spain	N01266 306	Madrid
Spain	N01266 301	Palma De Mallorca
Spain	N01266 248	Sevilla
Spain	N01266 308	Valencia
United Kingdom	N01266 215	London
United States	N01266 106	Boston	Massachusetts
United States	N01266 105	Buffalo	New York
United States	N01266 113	Chesterfield	Missouri
United States	N01266 118	Chicago	Illinois
United States	N01266 107	Cincinnati	Ohio
United States	N01266 111	Columbus	Ohio
United States	N01266 237	Durham	North Carolina
United States	N01266 108	Gulf Breeze	Florida
United States	N01266 117	Houston	Texas
United States	N01266 243	Los Angeles	California
United States	N01266 252	New York	New York
United States	N01266 114	Pittsburgh	Pennsylvania
United States	N01266 104	Rochester	New York
United States	N01266 101	Saint Paul	Minnesota
United States	N01266 103	Wellington	Florida

Sponsors (1)

Lead Sponsor	Collaborator
UCB Pharma SA

Countries where clinical trial is conducted

United States,  Belgium,  Czechia,  France,  Germany,  Hungary,  Ireland,  Italy,  Mexico,  Poland,  Spain,  United Kingdom, 

References & Publications (1)

Lagae L, Klotz KA, Fogarasi A, Floricel F, Reichel C, Elshoff JP, Fleyshman S, Kang H. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial. Epilepsia. 2023 Nov;64(11):2934-2946. doi: — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study	TEAEs are defined as AEs that had onset on or after the day of first BRV dose.	From Baseline to end of study (up to 10 years)
Primary	Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study	TEAEs are defined as AEs that had onset on or after the day of first BRV dose. A SAE was defined as an event that met 1 or more of the below criteria: a) Death, b) Life-threatening, (Life-threatening did not include a reaction that might have caused death had it occurred in a more severe form.) c) Significant or persistent disability/incapacity, d) Congenital anomaly/birth defect (including that occurring in a fetus), e) Important medical event that, based upon appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious, (Important medical events may have included allergic bronchospasm requiring intensive treatment in an emergency room [ER] or at home) f) Initial inpatient hospitalization or prolongation of hospitalization. (A participant admitted to a hospital, even if released on the same day, met the criteria for the initial inpatient hospitalization).	From Baseline to end of study (up to 10 years)
Secondary	Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged =2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])	Absolute change in seizure frequency per 28 days based on the daily record card (DRC) data, is calculated as baseline seizure frequency per 28 days minus post-Baseline seizure frequency per 28 days. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants =2 years (per DRC data) only.; Here in the study FAS indicates Full Analysis Set, EEG indicates electroencephalogram, OM indicates Outcome measure	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Secondary	Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged =2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)	Percent change is calculated as absolute change in seizure frequency per 28 days divided by baseline seizure frequency per 28 Days multiplied to 100. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants =2 years (per DRC data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Secondary	50% Responder Rate for Participants =2 Years of Age for Total Seizures (All Types) (Based on DRC Data)	A responder is defined as a participant with a =50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants or during this study for DE participants. This OM was analyzed in participants =2 years (per DRC data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Secondary	Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)	Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants <2 years (per EEG data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Secondary	Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)	Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants <2 years (per EEG data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Secondary	50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)	A responder is defined as a participant with a =50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants. This OM was analyzed in participants <2 years (per EEG data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Secondary	Absolute Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)	Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Secondary	Percent Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)	Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Secondary	50% Responder Rate for Total Seizures (All Types) in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)	A responder is defined as a participant with a =50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

External Links

•   FDA Safety Alerts and Recalls
•   Product Information